The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $76.69 in the prior trading day, Intra-Cellular Therapies Inc (NASDAQ: ITCI) closed at $72.00, down -6.12%. In other words, the price has decreased by -$6.12 from its previous closing price. On the day, 4.71 million shares were traded. ITCI stock price reached its highest trading level at $75.075 during the session, while it also had its lowest trading level at $71.205.
Ratios:
Our goal is to gain a better understanding of ITCI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.31 and its Current Ratio is at 5.41. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on January 03, 2024, initiated with a Outperform rating and assigned the stock a target price of $83.
On December 11, 2023, TD Cowen started tracking the stock assigning a Outperform rating and target price of $75.
On April 20, 2023, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $80.Morgan Stanley initiated its Overweight rating on April 20, 2023, with a $80 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when Mates Sharon sold 20,565 shares for $65.21 per share. The transaction valued at 1,341,123 led to the insider holds 1,050,309 shares of the business.
Hineline Lawrence J. sold 10,121 shares of ITCI for $667,587 on Mar 11 ’24. The SVP of Finance, CFO now owns 0 shares after completing the transaction at $65.96 per share. On Mar 11 ’24, another insider, Halstead Michael, who serves as the EVP and General Counsel of the company, sold 7,345 shares for $65.97 each. As a result, the insider received 484,537 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ITCI now has a Market Capitalization of 7018401792 and an Enterprise Value of 6489114624. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.01 while its Price-to-Book (P/B) ratio in mrq is 11.73. Its current Enterprise Value per Revenue stands at 13.974 whereas that against EBITDA is -40.85.
Stock Price History:
Over the past 52 weeks, ITCI has reached a high of $84.89, while it has fallen to a 52-week low of $45.50. The 50-Day Moving Average of the stock is 4.07%, while the 200-Day Moving Average is calculated to be 16.28%.
Shares Statistics:
The stock has traded on average 882.90K shares per day over the past 3-months and 1858970 shares per day over the last 10 days, according to various share statistics. A total of 96.38M shares are outstanding, with a floating share count of 94.22M. Insiders hold about 2.67% of the company’s shares, while institutions hold 93.14% stake in the company. Shares short for ITCI as of 1711584000 were 3465117 with a Short Ratio of 3.92, compared to 1709164800 on 3695471. Therefore, it implies a Short% of Shares Outstanding of 3465117 and a Short% of Float of 4.1500002.
Earnings Estimates
Intra-Cellular Therapies Inc (ITCI) is currently under the scrutiny of Intra-Cellular Therapies Inc. analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $90.49, with high estimates of $4.59 and low estimates of $0.38.
Analysts are recommending an EPS of between $Technology and $Technology for the fiscal current year, implying an average EPS of $Technology.
